BioSpace News Archive

The global market for immunoassay is fragmented in nature with a high number of players engaged in it across the globe, states a new research report by Transparency Market Research.

Ventyx Biosciences, Inc. announced the appointment of Sheila Gujrathi, M.D. to the Board of Directors as Executive Chair and Jörn Drappa, M.D., Ph.D. as Chief Medical Officer, as well as the closing of a $51.0 million Series B convertible preferred stock financing round.

ChromaDex Corp. announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen® in various health outcomes.

BioCryst Pharmaceuticals, Inc. announced that the company has appointed regulatory expert and former deputy center director of the U.S. Food and Drug Administration Oncology Center of Excellence, Amy McKee, M.D., to its board of directors.

PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular diseases, announced that Chief Executive Officer James McArthur, Ph.D., will present on Pepgen’s Enhanced Delivery Oligonucleotide therapeutic platform at two scientific conferences in September.

Gritstone bio, Inc. announced that the first volunteer has been dosed in a Phase 1 trial evaluating the ability of GRT-R910, a self-amplifying mRNA second generation SARS-CoV-2 vaccine to boost and expand the immunogenicity of first-generation COVID-19 vaccines in subjects 60 years of age or older.

Anavex Life Sciences Corp. announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 10:40 AM.

Enveric Biosciences, a biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform for the mind and body using psychedelics and cannabinoids, announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming investor conferences.

Glaukos Corporation announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc.

Mindset Pharma Inc. today announced that preclinical proof-of-concept data comparing its clinical candidate, MSP-4018, against 5-MeO-DMT